Project Grant R01HL173930
Award Date
9/5/24
Completion Date
7/31/28
Dollars Obligated
$1.9M
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
This $2,960,139 Project Grant, awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) on September 5, 2024, supports a comprehensive research project focused on assessing sudden cardiac death (SCD) risk and providing mechanistic insights in patients with arrhythmic mitral valve prolapse (MVP). The project aims to: 1) Perform deep phenotyping of MVP patients to understand characteristics and mechanisms associated with ventricular arrhythmias;...
This federal Project Grant award of $1,386,399.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to Yale University is for a research project titled "Unraveling Molecular Complexity of Mitral Valve Disease Using Single Cell and Spatial Multi-Omics Analysis". The project aims to construct a single-cell and spatial molecular atlas using mitral valve leaflet samples from both mitral valve prolapse (MVP) patients and healthy individuals....
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $125,250 to The General Hospital Corporation (doing business as Massachusetts General Hospital) to conduct a 2-year research study on the role of the cytokine FAM3D in heart failure. The principal investigator, Dr. James Rhee, will lead a team of scientists to investigate how FAM3D regulates cardiac fibroblasts and the lymphatic system to limit inflammation and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $2,940,607 to IHC Health Services Inc. (Intermountain Healthcare) to enhance clinical identification of individuals at risk of moderate to severe mitral valve prolapse (MVP) and associated adverse health outcomes. The project aims to: 1) describe the history of MVP, related cardiac morbidities, and contributing conditions using Intermountain...
This $604,115 federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will support a longitudinal observational study by The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop non-invasive advanced imaging technologies to predict the development of progressive pulmonary fibrosis in individuals with non-idiopathic pulmonary fibrosis interstitial lung...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $172,800 Project Grant under CFDA 93.837 - Cardiovascular Diseases Research to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant, awarded on July 20, 2025, will fund research to predict the hemodynamic response to mitral valve interventions using pressure-volume analysis. The research aims to: 1) identify new echocardiographic measures of left ventricular systolic function in...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under CFDA 93.837 - Cardiovascular Diseases Research provides $777,258 to Beth Israel Deaconess Medical Center, Inc. (BIDMC) to conduct research focused on unraveling the mechanisms of heart failure in hypertrophic cardiomyopathy. The 5-year project aims to improve understanding of heart failure in hypertrophic cardiomyopathy through novel cardiac magnetic resonance imaging (CMR) phenotyping techniques,...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of the long non-coding RNA SALTE1 in vascular aging and heart failure with preserved ejection fraction (HFPEF). The $708,266 award to The General Hospital Corporation (doing business as Massachusetts General Hospital) will fund a 4-year research project to determine the role of SALTE1 in vascular aging and HFPEF, and examine the underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research into the role of mitochondrial signaling between cardiomyocytes and fibroblasts in cardiac fibrosis. The $639,621 award, granted on May 15, 2025, will fund a research project led by Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to investigate how intact mitochondria released from cardiomyocytes mediate...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $785,198 to the Albert Einstein College of Medicine in Bronx, NY to study the role of chaperone-mediated autophagy (CMA) in regulating cardiac fibroblast and myofibroblast function and its impact on heart repair following myocardial infarction. The research aims to investigate how CMA modulates the proteomic profile, phenotype, and function of reparative...